Clinical Trial: A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07896460) titled 'A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors' on Oct. 21.

Brief Summary: The purpose of this study is to test if the BG-92505 is safe and if it works in patients with advanced solid tumors when it is given on its own or in combination with anti-cancer agents.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: DRUG: BG-92505

Administered orally.

DRUG: Anti-Cancer Agent

Administered by intravenous infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: BeOne Medicines

Disclaimer: Curated by H...